Erasca assumed with an Outperform at Mizuho

Mizuho analyst Joseph Catanzaro assumed coverage of Erasca (ERAS) with an Outperform rating and price target of $16, up from $5. The firm says the company’s RAS inhibitor portfolio is well positioned to establish proof-of-concept in 2026. ERAS-0015 has opportunity for a wider therapeutic window and a competitive clinical profile, the analyst tells investors in a research note.